Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CANF OTCMKTS:CRVW NASDAQ:TENX NASDAQ:VERO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$0.52+6.9%$0.64$0.47▼$3.12$1.86M1.01211,533 shs857,370 shsCRVWCareview Communications$0.02+11.1%$0.02$0.01▼$0.05N/A-0.4131,227 shs157,260 shsTENXTenax Therapeutics$6.99-6.9%$6.47$3.65▼$8.24$31.90M1.5841,433 shs85,716 shsVEROVenus Concept$2.40-0.8%$2.36$2.10▼$14.50$3.41M0.05852,868 shs21,861 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma-4.74%-18.62%-26.09%-53.11%-80.56%CRVWCareview Communications-19.80%-15.18%+11.72%-18.59%-66.67%TENXTenax Therapeutics+1.35%+0.27%+22.91%+28.38%+98.15%VEROVenus Concept+3.86%+2.11%+3.86%-0.82%-54.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCANFCan-Fite BioPharma$0.52+6.9%$0.64$0.47▼$3.12$1.86M1.01211,533 shs857,370 shsCRVWCareview Communications$0.02+11.1%$0.02$0.01▼$0.05N/A-0.4131,227 shs157,260 shsTENXTenax Therapeutics$6.99-6.9%$6.47$3.65▼$8.24$31.90M1.5841,433 shs85,716 shsVEROVenus Concept$2.40-0.8%$2.36$2.10▼$14.50$3.41M0.05852,868 shs21,861 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCANFCan-Fite BioPharma-4.74%-18.62%-26.09%-53.11%-80.56%CRVWCareview Communications-19.80%-15.18%+11.72%-18.59%-66.67%TENXTenax Therapeutics+1.35%+0.27%+22.91%+28.38%+98.15%VEROVenus Concept+3.86%+2.11%+3.86%-0.82%-54.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCANFCan-Fite BioPharma 3.00Buy$14.502,667.18% UpsideCRVWCareview Communications 0.00N/AN/AN/ATENXTenax Therapeutics 2.83Moderate Buy$18.00157.51% UpsideVEROVenus Concept 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CRVW, CANF, TENX, and VERO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025TENXTenax TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025VEROVenus ConceptWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TENXTenax TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VEROVenus ConceptWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/16/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/8/2025TENXTenax TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.009/2/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/14/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $14.007/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCANFCan-Fite BioPharma$560K3.31N/AN/A$1.76 per share0.30CRVWCareview Communications$8.25MN/AN/AN/A($0.28) per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$26.99 per shareN/AVEROVenus Concept$64.83M0.05N/AN/A$4.30 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/ACRVWCareview Communications-$4.70MN/A0.00∞N/A-46.96%N/A-94.89%N/ATENXTenax Therapeutics-$17.60M-$0.92N/AN/AN/AN/A-31.34%-30.39%11/12/2025 (Estimated)VEROVenus Concept-$47M-$50.78N/A∞N/A-68.77%-871.77%-61.92%11/13/2025 (Estimated)Latest CRVW, CANF, TENX, and VERO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TENXTenax Therapeutics-$1.33N/AN/AN/AN/AN/A8/14/2025Q2 2025VEROVenus Concept-$9.72-$8.03+$1.69-$8.03$14.01 million$15.69 million8/13/2025Q2 2025TENXTenax Therapeutics-$0.50-$0.27+$0.23-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCANFCan-Fite BioPharmaN/AN/AN/AN/AN/ACRVWCareview CommunicationsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/AVEROVenus ConceptN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCANFCan-Fite BioPharmaN/A2.93N/ACRVWCareview CommunicationsN/A0.090.08TENXTenax TherapeuticsN/A41.8941.89VEROVenus Concept5.721.100.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCANFCan-Fite BioPharma21.00%CRVWCareview CommunicationsN/ATENXTenax Therapeutics1.67%VEROVenus Concept87.41%Insider OwnershipCompanyInsider OwnershipCANFCan-Fite BioPharma0.80%CRVWCareview Communications63.94%TENXTenax Therapeutics3.70%VEROVenus Concept28.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableCRVWCareview Communications60N/AN/ANot OptionableTENXTenax Therapeutics94.56 million4.39 millionNot OptionableVEROVenus Concept4101.42 million1.03 millionNot OptionableCRVW, CANF, TENX, and VERO HeadlinesRecent News About These CompaniesVenus Concept Inc. (NASDAQ:VERO) Short Interest Up 54.8% in SeptemberOctober 8, 2025 | americanbankingnews.comVenus Concept Inc. Announces $11.48 Million Debt Exchange for Preferred Stock, Reducing Overall Debt by 24%October 2, 2025 | quiverquant.comQVenus Concept Reduces Debt with Equity ExchangeOctober 2, 2025 | tipranks.comVenus Concept Announces $11.48 Million Debt-to-Equity Exchange TransactionOctober 2, 2025 | globenewswire.comVenus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025October 1, 2025 | globenewswire.comVenus Concept Secures $2M Loan for Working CapitalSeptember 22, 2025 | tipranks.comCellulite Treatment Market Size to Reach USD 5.19 Billion by 2032, Driven by Rising Demand for Non-Invasive Aesthetic Solutions | S&S InsiderSeptember 19, 2025 | globenewswire.comVenus Concept Secures Financial Relief with New AgreementsSeptember 4, 2025 | msn.comVenus Concept Secures $2M Loan for OperationsAugust 26, 2025 | tipranks.comAnalysts Conflicted on These Healthcare Names: Venus Concept (VERO) and TuHURA Biosciences (HURA)August 22, 2025 | theglobeandmail.comVenus Concept Inc. (NASDAQ:VERO) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVenus Concept Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comVenus Concept Inc. (VERO) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comVenus Concept Amends Loan Agreements for Financial ReliefAugust 14, 2025 | theglobeandmail.comVenus Concept Announces Second Quarter 2025 Financial ResultsAugust 14, 2025 | globenewswire.comVenus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025July 16, 2025 | globenewswire.comVenus Concept Inc. to Release Q2 Fiscal 2025 Financial Results on August 14, 2025, with Conference Call DetailsJuly 16, 2025 | quiverquant.comQVERO - Venus Concept Inc Financials - MorningstarJuly 8, 2025 | morningstar.comMVenus Concept Executes Debt-to-Equity Exchange AgreementJuly 1, 2025 | tipranks.comVenus Concept Announces $6.5 Million Debt-to-Equity Exchange TransactionJuly 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVW, CANF, TENX, and VERO Company DescriptionsCan-Fite BioPharma NYSE:CANF$0.52 +0.03 (+6.94%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Careview Communications OTCMKTS:CRVW$0.02 +0.00 (+11.11%) As of 01:26 PM EasternCareView Communications, Inc. provides video monitoring solutions in the United States. Its products include CareView Patient Safety System, a video monitoring tool to improve the practice of nursing, create a better work environment, and make the patient's hospital stay more satisfying, which is used in hospitals, nursing homes, adult living centers, and outpatient care facilities; and CareView Connect, which provides resident monitoring products and services for the long- term care industry; an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance; a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert; and alert management and monitoring system that provides a suite of hardware and software to facilitate a data-driven solution for alert management and monitoring. The company also offers Caregiver Platform that offers caregiver connect mobile application to provide a convenient and intuitive interface to capture critical workflows, such as acknowledging and documenting alert presses by the resident. In addition, it provides SitterView and TeleMedView that allows hospital staff to use CareView's video cameras to observe and communicate with patients remotely. CareView Communications, Inc. is based in Lewisville, Texas.Tenax Therapeutics NASDAQ:TENX$6.99 -0.52 (-6.92%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Venus Concept NASDAQ:VERO$2.40 -0.02 (-0.83%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
